Drug Target Review: Could a nasal spray prevent COVID-19?

A UC study shows that a lipid might prevent infection and could potentially be easily administered

According to a study led by UC researchers, the lipid sphingosine may have the ability to inhibit SARS-CoV-2 infection and could potentially be delivered in a nasal spray to prevent COVID-19 infections.

Researchers, led by a visiting professor in the UC Department of Surgery Erich Gulbins, MD,  have examined pre-existing research into bacterial respiratory tract infections and applied the findings to COVID-19, with some success. According to the scientists, a sphingosine nasal spray could potentially prevent or treat SARS-CoV-2 infections.

“We investigated whether a specific lipid [sphingosine] is able to interfere with the binding of SARS-CoV-2 to human epithelial cells,” said Gulbins, corresponding author on the study, published in the Journal of Biological Chemistry. 

Read the full story.

Read the UC News release.

Featured photo of the lipid sphingosine courtesy of Jynto.

Next Lives Here

The University of Cincinnati is classified as a Research 1 institution by the Carnegie Commission and is ranked in the National Science Foundation's Top-35 public research universities. UC's graduate students and faculty investigate problems and innovate solutions with real-world impact. Next Lives Here.

Related Stories

2

A day of hoops and fun supports families impacted by homelessness

April 6, 2026

CPS All-Star Showcase returned to UC’s Fifth Third Arena, Saturday, April 4, highligting the partnership between Cincinnati Public Schools and the University of Cincinnati. Local media covered the daylong sports event which showcased some Cincinnati's finest high school athletes. Proceeds from the event benefited Project Connect.

3

What is the 'cicada' COVID variant?

April 6, 2026

A formerly rare strain of COVID, BA.3.2, now is showing up in Ohio and 24 other states. Experts say so far it hasn't caused illness any more severe than other strains, but it might be somewhat more resistant to vaccines, as 91.7 WVXU News recently reported. Scientists have nicknamed the variant "cicada" due to its former low profile and current resurgence.